Symbols

PTN

Palatin Technologies·AMEX

--(--)

PTN fundamentals

PTN Q2 2026 Earnings

Palatin Technologies (PTN) released its earnings on Feb 17, 2026: revenue was 25.00K (YoY --), met estimates; EPS was -2.86 (YoY +52.33%), missed estimates.

Revenue / YoY

25.00K

EPS / YoY

-2.86

+52.33%

Report date

Feb 17, 2026

PTN Earnings Call Summary for Q2,2026

$18.2M Public Offering Success: Restored NYSE listing and strengthened balance sheet for pipeline advancement.
Revenue Growth: $116,000 from Boehringer collaboration, up from $0 prior year.
Pipeline Milestones: PL-7737 IND submission and Phase I trial in Q2 2026; next-gen peptide IND in H2 2026.
Strategic Focus: Rare obesity disorders (HO, PWS) with differentiated MC4R agonists targeting reduced side effects.
Cash Runway: $14.5M as of Dec 2025, extending into 2027.
Q&A Highlights: Confidence in PL-7737's safety profile; potential for MC4R/GLP-1 combination therapies.

Earnings

EPS

Revenue

Revenue & Expenses

PTN has released its 2026 Q2 earnings report, with revenue of 116.04K, reflecting a YoY change of NaN%, and net profit of -7.26M, showing a YoY change of -197.40%. The Sankey diagram below clearly presents PTN's revenue sources and cost distribution.

Key Indicators

Palatin Technologies (PTN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Palatin Technologies (PTN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Palatin Technologies (PTN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Palatin Technologies (PTN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown